Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.63 |
| ▸ | HTR2B | P41595 | 10/20 | 0.63 |
| ▸ | HTR2A | P28223 | 9/20 | 0.63 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15522728 | 0.84 | HTR2C (0.50) | HTR2CHTR2BHTR2AMAP2K1 | |
| SCHEMBL15522748 | 0.84 | HTR2C (0.50) | HTR2CHTR2BHTR2AMAP2K1 | |
| SCHEMBL15523416 | 0.82 | HTR2C (0.64) | HTR2CHTR2BHTR2A | |
| SCHEMBL15522674 | 0.82 | HTR2C (0.61) | HTR2CHTR2BHTR2AMAP2K1 | |
| SCHEMBL6746387 | 0.81 | MAP2K1 (0.56) | HTR2CHTR2BHTR2AMAP2K1 | |
| SCHEMBL15522869 | 0.79 | HTR2C (0.45) | HTR2CHTR2BHTR2A | |
| SCHEMBL6746228 | 0.79 | MAP2K1 (0.53) | HTR2CHTR2BHTR2AMAP2K1 | |
| SCHEMBL15522698 | 0.78 | HTR2C (0.44) | HTR2CHTR2BHTR2AMAP2K1 | |
| SCHEMBL16691521 | 0.77 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL11884369 | 0.75 | HTR2C (0.50) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-09-10 | — | — | US | claimed |
| US-20190071443-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-03-07 | — | — | US | claimed |
| US-20160016954-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-21 | — | — | US | claimed |
| US-9169253-B2 | Tricyclic quinoline and quinoxaline derivatives | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-27 | — | — | US | claimed |
| EP-2895485-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-07-22 | — | — | EP | claimed |
| US-20140080814-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-20 | — | — | US | claimed |
| US-20140080816-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-20 | — | — | US | claimed |
| WO-2014041131-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-20 | — | — | WO | claimed |
| US-20140080813-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | ABBVIE DEUTSCHLAND (DE) | 2014-03-20 | — | — | US | claimed |
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-09-10 | — | — | US | disclosed |
| US-20190071443-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-03-07 | — | — | US | disclosed |
| US-20190048007-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-02-14 | — | — | US | disclosed |
| US-10118926-B2 | Tricyclic quinoline and quinoxaline derivatives | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-11-06 | — | — | US | disclosed |
| US-9994568-B2 | Tricyclic quinoline and quinoxaline derivatives | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9169253-B2 | Tricyclic quinoline and quinoxaline derivatives | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-27 | — | — | US | disclosed |
| EP-2895485-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-20140080813-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | ABBVIE DEUTSCHLAND (DE) | 2014-03-20 | — | — | US | disclosed |
| WO-2014041131-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-20 | — | — | WO | disclosed |
| US-20140080814-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-20 | — | — | US | disclosed |
| US-20140080816-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080813-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 8/4885HTR2A 2/4885 |
| US-20160016954-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 8/4885HTR2A 2/4885 |
| US-20140080816-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 8/4885HTR2A 2/4885 |
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 8/4885HTR2A 2/4885 |
| US-20190048007-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 8/4885HTR2A 2/4885 |
| US-20140080814-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 8/4885HTR2A 2/4885 |
| US-10118926-B2 | Tricyclic quinoline and quinoxaline derivatives | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 8/4885HTR2A 2/4885 |
| US-20190071443-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 8/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.